A decision to invalidate the patent for Amgen's blockbuster is ominous for future gene patents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kirin-Amgen Inc. and others (Appellants) versus Hoechst Marion Roussel Ltd and others (Respondents), House of Lords, 21 October 2004 [2004] UKHL 46 (http://www.parliament.the-stationery-office.co.uk/pa/ld200304/ldjudgmt/jd041021/kirin-1.htm).
Protocol on the Interpretation of EPC Article 69 (footnote to Article).
PC Article 64(2).
Author information
Author notes
R. Stephen Crespi is a patent attorney based in West Sussex, UK.
- R Stephen Crespi
Rights and permissions
About this article
Cite this article
Crespi, R. Erythropoietin in the UK: a setback for gene patents?. Nat Biotechnol 23, 367–368 (2005). https://doi.org/10.1038/nbt0305-367
Issue Date:
DOI: https://doi.org/10.1038/nbt0305-367
